Table Of Contents
1. Market Context & Strategic Relevance
1.1 Opening Context (Why the market matters)
1.1.1 Why This Market Is Gaining Strategic Attention
1.1.2 Business Decisions This Report Supports
1.2 Scope
1.3 Research & Methodology
2. Executive Summary
2.1 Market Snapshot
2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis
2.3 Market Size & Forecast, By Segmentation, 2022–2035
2.3.1 Market Size By Indication
2.3.2 Market Size By Route of Administration
2.3.3 Market Size By Distribution Channel
2.3.4 Market Size By Product Type
2.4 Market Share & Bps Analysis By Region, 2025
2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic
2.6 Industry CxO's Perspective
3. Market Overview
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Key Market Trends
3.2 Industry PESTLE Analysis
3.3 Key Industry Forces (Porter's) Impacting Market Growth
3.4 Industry Supply Chain Analysis
3.4.1. Active Pharmaceutical Ingredient & Biologic Manufacturing
3.4.2. Formulation, Fill-Finish & Device Assembly
3.4.3. Regulatory Filing, Licensing & Distribution Partnerships
3.4.4. Specialty Pharmacy, Hospital & Patient Dispensing
3.5 Industry Life Cycle Assessment
4. Statistical Insights & Trends Reporting
4.1 Biosimilar Pipeline & Regulatory Tracking
4.1.1 Secukinumab Biosimilar Filing Timeline Mapping
4.1.2 Regional Regulatory Pathway Benchmarking
4.1.3 Patent Expiry & Exclusivity Tracking
4.1.4 Approval Sequencing Risk Analysis
4.2 Competitive Class Benchmarking
4.2.1 IL-17 vs IL-23 vs TYK2 Inhibitor Positioning
4.2.2 Label Expansion & Indication Overlap Mapping
4.2.3 Head-to-Head Trial Outcome Tracking
4.2.4 Pricing & Contracting Comparison by Molecule
4.3 Distribution & Access Intelligence
4.3.1 Specialty Pharmacy Channel Share Tracking
4.3.2 Payer Utilization Management Benchmarking
4.3.3 Online vs Hospital Dispensing Trend Analysis
4.3.4 Patient Switching Pattern Mapping
4.4 Regional Commercialization Strategy
4.4.1 Licensing Partnership Mapping by Geography
4.4.2 Asia Pacific Biosimilar Developer Tracking
4.4.3 First-Mover Market Entry Benchmarking
4.4.4 Cross-Border Filing Sequence Analysis
4.5 Originator Defense Strategy Intelligence
4.5.1 Label Expansion Pipeline Tracking
4.5.2 Device & Formulation Differentiation Benchmarking
4.5.3 Real-World Evidence Generation Mapping
4.5.4 Biosimilar Response Strategy Analysis
5. Cosentyx Drug Market Segmental Analysis, By Indication
5.1 Introduction
5.2 Plaque Psoriasis
5.2.1 Key Trends
5.2.2 Market Size & Forecast, 2022–2035
5.3 Psoriatic Arthritis
5.4 Ankylosing Spondylitis
5.5 Non-Radiographic Axial Spondyloarthritis
5.6 Others
6. Cosentyx Drug Market Segmental Analysis, By Route of Administration
6.1 Introduction
6.2 Subcutaneous
6.2.1 Key Trends
6.2.2 Market Size & Forecast, 2022–2035
6.3 Intravenous
6.4 Others
7. Cosentyx Drug Market Segmental Analysis, By Distribution Channel
7.1 Introduction
7.2 Hospital Pharmacies
7.2.1 Key Trends
7.2.2 Market Size & Forecast, 2022–2035
7.3 Retail Pharmacies
7.4 Specialty Pharmacies
7.5 Online Pharmacies
8. Cosentyx Drug Market Segmental Analysis, By Product Type
8.1 Introduction
8.2 Originator Brand
8.2.1 Key Trends
8.2.2 Market Size & Forecast, 2022–2035
8.3 Biosimilars
9. Cosentyx Drug Market Segmental Analysis, By Region
9.1 Introduction
9.2 North America
9.2.1 Key Trends
9.2.2 Cosentyx Drug Market Size & Forecast, By Indication, 2022–2035
9.2.3 Cosentyx Drug Market Size & Forecast, By Route of Administration, 2022–2035
9.2.4 Cosentyx Drug Market Size & Forecast, By Distribution Channel, 2022–2035
9.2.5 Cosentyx Drug Market Size & Forecast, By Product Type, 2022–2035
9.2.6 Cosentyx Drug Market Size & Forecast, By Country, 2022–2035
9.2.6.1 US
9.2.6.2 Canada
9.3 Europe
9.3.1 Key Trends
9.3.2 Cosentyx Drug Market Size & Forecast, By Indication, 2022–2035
9.3.3 Cosentyx Drug Market Size & Forecast, By Route of Administration, 2022–2035
9.3.4 Cosentyx Drug Market Size & Forecast, By Distribution Channel, 2022–2035
9.3.5 Cosentyx Drug Market Size & Forecast, By Product Type, 2022–2035
9.3.6 Cosentyx Drug Market Size & Forecast, By Country, 2022–2035
9.3.6.1 Germany
9.3.6.2 France
9.3.6.3 UK
9.3.6.4 Italy
9.3.6.5 Spain
9.3.6.6 Poland
9.3.6.7 Russia
9.3.6.8 Rest of Europe
9.4 Asia Pacific
9.4.1 Key Trends
9.4.2 Cosentyx Drug Market Size & Forecast, By Indication, 2022–2035
9.4.3 Cosentyx Drug Market Size & Forecast, By Route of Administration, 2022–2035
9.4.4 Cosentyx Drug Market Size & Forecast, By Distribution Channel, 2022–2035
9.4.5 Cosentyx Drug Market Size & Forecast, By Product Type, 2022–2035
9.4.6 Cosentyx Drug Market Size & Forecast, By Country, 2022–2035
9.4.6.1 China
9.4.6.2 India
9.4.6.3 Japan
9.4.6.4 South Korea
9.4.6.5 Australia
9.4.6.6 ASEAN Countries
9.4.6.7 Rest of Asia Pacific
9.5 Latin America
9.5.1 Key Trends
9.5.2 Cosentyx Drug Market Size & Forecast, By Indication, 2022–2035
9.5.3 Cosentyx Drug Market Size & Forecast, By Route of Administration, 2022–2035
9.5.4 Cosentyx Drug Market Size & Forecast, By Distribution Channel, 2022–2035
9.5.5 Cosentyx Drug Market Size & Forecast, By Product Type, 2022–2035
9.5.6 Cosentyx Drug Market Size & Forecast, By Country, 2022–2035
9.5.6.1 Brazil
9.5.6.2 Argentina
9.5.6.3 Mexico
9.5.6.4 Colombia
9.5.6.5 Rest of Latin America
9.6 Middle East & Africa
9.6.1 Key Trends
9.6.2 Cosentyx Drug Market Size & Forecast, By Indication, 2022–2035
9.6.3 Cosentyx Drug Market Size & Forecast, By Route of Administration, 2022–2035
9.6.4 Cosentyx Drug Market Size & Forecast, By Distribution Channel, 2022–2035
9.6.5 Cosentyx Drug Market Size & Forecast, By Product Type, 2022–2035
9.6.6 Cosentyx Drug Market Size & Forecast, By Country, 2022–2035
9.6.6.1 UAE
9.6.6.2 Saudi Arabia
9.6.6.3 Qatar
9.6.6.4 South Africa
9.6.6.5 Rest of Middle East & Africa
10. Competitive Landscape
10.1 Key Players' Positioning
10.2 Competitive Developments
10.2.1 Year-Wise Strategies & Development, 2022–2026
10.3 Market Share Analysis, 2025
10.4 Product/Service & Application Benchmarking
10.4.1 Product/Service Specifications & Features By Key Players
10.4.2 Product/Service Heatmap By Key Players
10.4.3 Application Heatmap By Key Players
10.5 Industry Start-Up & Innovation Landscape
10.6 Key Company Profiles
10.6.1 Novartis International AG
10.6.1.1 Company Overview & Snapshot
10.6.1.2 Product/Service Portfolio
10.6.1.3 Key Company Financials
10.6.1.4 Geographical Presence
10.6.1.5 SWOT Analysis
10.6.2 Celltrion, Inc.
10.6.3 CSPC Pharmaceutical Group Limited
10.6.4 Bio-Thera Solutions, Ltd.
10.6.5 Taizhou Mabtech Pharma & Biotech Co., Ltd.
10.6.6 Livzon Pharmaceutical Group Inc.
10.6.7 Dr. Reddy's Laboratories Ltd.
11. Analyst Recommendations
11.1 SNS Insider Opportunity Map
11.2 Industry Low-Hanging Fruit Assessment
11.3 Market Entry & Growth Strategy
11.4 Analyst Viewpoint & Suggestions On Market Growth
12. Assumptions
13. Disclaimer
14. Appendix
14.1 List Of Tables
14.2 List Of Figures
Frequently Asked Questions
The market includes Novartis, Celltrion, CSPC Pharmaceutical Group, Bio-Thera Solutions, among others. These companies compete through the originator brand, a growing field of secukinumab biosimilar candidates, and rival IL-17, IL-23 and TYK2 inhibitor franchises.
The main opportunities lie in licensing and commercialization partnerships that let biosimilar developers reach new geographic markets quickly, and in first-mover positioning within regions where biosimilar competition against Cosentyx has not yet arrived.
The key growth factor is the unusually large number of secukinumab biosimilar programs advancing through regulatory stages simultaneously, which is expected to accelerate competitive entry once the first approval is secured.
By indication, the Plaque Psoriasis segment dominated the market with approximately 52.40% share in 2025, reflecting its status as secukinumab's original and most established approved use.
North America dominated the market with approximately 45.80% share in 2025, supported by the deepest established prescriber base for IL-17 and IL-23 inhibitors. Asia Pacific is the fastest-growing region with a projected CAGR of 8.60% from 2026 to 2035.
